Related Experiment Video
Updated: Mar 24, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Alcohol Modulation of Amyloid Precursor Protein in Alzheimer's Disease
Steven A Masi1, Madhavan P Nair2, Michael Vigorito3
1Institute of Neuroimmune Pharmacology, Seton Hall University, South Orange, USA.
None:
Heavy alcohol use increases the risk of Alzheimer's Disease (AD); however, the underlying mechanisms are not addressed. The key chemical of alcohol beverages is ethanol (EtOH), and acetaldehyde is its key toxic metabolite. QIAGEN Ingenuity Pathway Analysis (IPA) bioinformatics tool was used to investigate and compare the holistic impact of EtOH and acetaldehyde on AD. An extensively researched biomarker of AD pathologies is amyloid-beta of which the precursor is amyloid precursor protein (APP). Molecules associated with APP or EtOH were collected from the QIAGEN Knowledge Base, and 313 molecules were overlapping between the molecule sets. Using the "Pathway Explorer" tool, 40 of the 313 molecules were found to change due to EtOH exposure and influence APP and were compared with acetaldehyde-mediated molecule expression changes. A pathway analysis of the findings related to these 40 molecules showed that EtOH increases APP expression at a confidence of p = 0.056 (z-score = 1.91, two-tailed). Among the top 10 IPA canonical pathways, ranked by the Benjamini-Hochberg corrected Fisher's Exact Test, identified through the "Core Expression Analysis" feature of IPA, revealed that neuroinflammation was associated at the highest confidence (p=5.97E-73). Our study suggests involvement of the neuroinflammation pathway in alcohol modulation of APP as a potential causal factor in AD.
More Related Videos
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...